# TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors

> **NCT07342738** · EARLY_PHASE1 · NOT_YET_RECRUITING · sponsor: **Sun Yat-sen University** · enrollment: 25 (estimated)

## Conditions studied

- KRAS G12V
- KRAS G12D
- Solid Tumor

## Interventions

- **BIOLOGICAL:** TCR-T cells
- **DRUG:** Fludarabine
- **DRUG:** Cyclophosphamide

## Key facts

- **NCT ID:** NCT07342738
- **Lead sponsor:** Sun Yat-sen University
- **Sponsor class:** OTHER
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-02-01
- **Primary completion:** 2028-02-01
- **Final completion:** 2029-02-01
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2026-01-15

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07342738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07342738, "TCR-T Cell Therapy for KRAS Mutation in Advanced Solid Tumors". Retrieved via AI Analytics 2026-08-17 from https://api.ai-analytics.org/clinical/NCT07342738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*